Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Integra Lifesciences Holdings (IART) Accumulated Depreciation & Amortization (2016 - 2025)

Integra Lifesciences Holdings' Accumulated Depreciation & Amortization history spans 16 years, with the latest figure at $444.0 million for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 11.85% to $444.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $444.0 million, a 11.85% increase, with the full-year FY2025 number at $444.0 million, up 11.85% from a year prior.
  • Accumulated Depreciation & Amortization hit $444.0 million in Q4 2025 for Integra Lifesciences Holdings, up from $396.9 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for IART hit a ceiling of $444.0 million in Q4 2025 and a floor of $314.9 million in Q4 2021.
  • Historically, Accumulated Depreciation & Amortization has averaged $370.6 million across 5 years, with a median of $367.4 million in 2023.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: rose 4.72% in 2022 and later grew 11.85% in 2025.
  • Tracing IART's Accumulated Depreciation & Amortization over 5 years: stood at $314.9 million in 2021, then increased by 4.72% to $329.7 million in 2022, then rose by 11.44% to $367.4 million in 2023, then increased by 8.02% to $396.9 million in 2024, then grew by 11.85% to $444.0 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for IART at $444.0 million in Q4 2025, $396.9 million in Q4 2024, and $367.4 million in Q4 2023.